Radioactive cancer drug, starting with raw materials in six years.

The government directly manages the isotope self-sufficiency system to raise the medical core radioisotope self-sufficiency rate used to treat cancer from the current 10% level to 100% by 2030.

Radiopharmaceuticals are treatments that destroy disease cells with radiation by attaching radioisotopes that emit radiation to derivatives such as peptides or antibodies.

It is an expanding market, with Novartis' prostate cancer treatment producing 1.4 trillion won in sales.

The Ministry of Science and ICT will advance its research reactors and proton accelerators and support the development of next-generation isotope production technologies such as ruthenium-177 and molybdenum-99.

The plan is to select isotopes that need to be managed nationally and to establish a self-sufficiency system to develop high-purity separation refining source technology.

In addition, it directly supports three key technologies: derivatives, synthesis optimization, and next-generation new drugs that diagnose and treat at the same time.